B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $216.65
    -1.85 (-0.85%)

    Market Cap: $32.28B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +11.12%
    Streak
    17 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.04
    Range$1.44 - $2.67
    25 analysts
    EPS Revisions
    7
    0
    7d
    0
    21
    30d
    EPS Estimate Drift
    90d ago$3.93+93.2%
    60d ago$3.93+93.3%
    30d ago$2.48+22.0%
    7d ago$2.04+0.0%
    Current$2.04
    Revenue Consensus
    $2.6B
    Range$2.5B - $2.7B
    25 analysts
    Dec 31, 2026
    EPS Consensus$5.40
    Range$4.98 - $5.98
    29 analysts
    Revenue Consensus
    $3.1B
    Range$2.8B - $3.3B
    30 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$5.40---
    Sep 26EST
    		-$2.04---
    Jun 26
    		$3.60$3.04+18.42%Beat-34.2%
    Mar 26
    		$3.57$2.89+23.53%Beat+18.2%
    Dec 25
    		$1.99$1.62+22.84%Beat-42.2%
    Sep 25
    		$4.81$3.88+23.97%Beat+17.9%
    Jun 25
    		$5.47$3.88+40.98%Beat+3.6%
    Mar 25
    		$3.02$2.95+2.37%Beat-17.7%
    Dec 24
    		$3.44$3.36+2.38%Beat+4.2%
    Sep 24
    		$4.08$3.79+7.65%Beat-6.4%
    Jun 24
    		$5.28$4.03+31.02%Beat+31.3%
    Mar 24
    		$3.67$3.46+6.07%Beat+7.9%
    Dec 23
    		$3.30$3.18+3.77%Beat-18.5%
    Sep 23
    		$4.36$3.98+9.55%Beat-8.6%
    Jun 23
    		$4.02$3.76+6.91%Beat-23.4%
    Mar 23
    		$3.40$3.28+3.66%Beat-6.1%
    Dec 22
    		$4.05$3.48+16.38%Beat+19.5%
    Sep 22
    		$4.77$4.13+15.50%Beat+0.0%
    Jun 22
    		$5.25$4.07+28.99%Beat-7.6%
    Mar 22
    		$3.62$4.36-16.97%Miss-32.2%
    Dec 21
    		$3.39$3.37+0.59%Beat-26.0%
    Sep 21
    		$4.77$4.10+16.34%Beat-46.0%
    Jun 21
    		$5.68$4.60+23.48%Beat-44.6%
    Mar 21
    		$5.34$4.94+8.10%Beat-41.6%
    Dec 20
    		$4.58$4.80-4.58%Miss-45.1%
    Sep 20
    		$8.84$8.05+9.81%Beat-3.6%
    Jun 20
    		$10.26$8.00+28.25%Beat+12.1%
    Mar 20
    		$9.14$7.69+18.86%Beat+30.9%
    Dec 19
    		$8.34$8.08+3.22%Beat+19.3%
    Sep 19
    		$9.17$8.27+10.88%Beat+23.9%
    Jun 19
    		$9.15$7.53+21.51%Beat+57.8%
    Mar 19
    		$6.98$6.96+0.29%Beat+15.4%
    Dec 18
    		$6.99$6.72+4.02%Beat+32.9%
    Sep 18
    		$7.40$6.76+9.47%Beat+17.3%
    Jun 18
    		$5.80$5.14+12.84%Beat+15.1%
    Mar 18
    		$6.05$5.94+1.85%Beat+16.3%
    Dec 17
    		$5.26$5.45-3.49%Miss+4.4%
    Sep 17
    		$6.31$5.72+10.31%Beat+21.6%
    Jun 17
    		$5.04$4.37+15.33%Beat-
    Mar 17
    		$5.20$4.97+4.63%Beat-
    Dec 16
    		$5.04$4.96+1.61%Beat-
    Sep 16
    		$5.19$4.97+4.43%Beat-

    Key Metrics

    Valuation
    P/E Ratio15.51EV/EBITDA18.60x
    Price/FCF11.87xFCF Yield8.43%
    Profitability
    Profit Margin8.32%Operating Margin25.10%
    ROE4.58%ROIC3.06%
    Financial Health
    Debt/Equity0.43xInterest CoverageN/A
    Current Ratio1.87xQuick Ratio1.26x
    Trading Statistics
    Beta0.16Avg Volume759.13K
    52-Week High$222.8552-Week Low$133.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$218.19
    SMA 20$213.03
    SMA 50$207.81
    SMA 200$189.92
    EMA 10$217.16
    EMA 20$214.01
    EMA 50$207.97
    EMA 200$188.75

    MACD

    Line: 3.98Signal: 3.65Hist: 0.33

    ADX

    ADX: 24.9+DI: 26.0-DI: 17.7

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$205.69

    Bollinger Bands

    Upper Band$224.77
    Lower Band$201.30
    %B Position1102%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    55.7

    Momentum Oscillators

    Stoch %K81.8
    Stoch %D87.5
    Williams %R-28.4
    ROC (10d)3.6%
    Momentum7.50
    CCI (20d)46.1
    MFI (14d)53.3

    Volatility Measures

    ATR (14d)$5.82(2.7%)
    StdDev (20d)5.87
    Hist Vol27.3%(Moderate)

    Volume Flow

    VWAP$216.37
    OBV39.3M
    AD Line7.5M
    CMF (20d)0.116

    Volume Metrics

    Avg Vol (20d)750.0K
    Vol Ratio1.1x
    VWMA (20d)$212.34

    Pivot Points

    R3$226.63
    R2$224.31
    R1$221.41
    Pivot Point$219.09
    S1$216.19
    S2$213.87
    S3$210.97

    Advanced Oscillators

    TSI17.12
    Ultimate Osc61.2
    KST57.64

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.74B$2.48B$2.28B$2.53B$2.65B$2.43B$2.45B$2.47B$2.46B$2.29B$2.39B$2.53B
    Cost of Revenue$776.90M$661.00M$495.50M$674.40M$605.00M$629.30M$583.50M$638.70M$546.00M$542.20M$618.30M$659.60M
    Gross Profit$1.96B$1.82B$1.78B$1.86B$2.04B$1.80B$1.87B$1.83B$1.92B$1.75B$1.77B$1.87B
    Operating Expenses$1.83B$1.44B$1.84B$1.30B$1.28B$1.49B$1.58B$1.38B$1.22B$1.28B$1.48B$2.01B
    R&D$693.60M$573.00M$731.80M$438.20M$445.60M$634.80M$532.30M$542.70M$513.90M$452.90M$570.90M$736.30M
    SG&A$709.70M$607.30M$682.50M$594.80M$583.80M$572.50M$680.00M$588.40M$553.80M$581.50M$608.50M$788.20M
    Operating Income$132.40M$377.70M$-56,000,000$557.30M$757.20M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M$-141,200,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$13.20M$0$0$0$0$0$0$0
    Income Before Tax$132.40M$377.70M$-56,000,000$557.30M$744.00M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M$-141,200,000
    Income Tax Expense$34.90M$58.20M$-7,100,000$90.80M$109.20M$70.70M$24.80M$62.50M$115.10M$71.40M$42.70M$-72,900,000
    Net Income$97.50M$319.50M$-48,900,000$466.50M$648.00M$240.50M$266.70M$388.50M$583.60M$393.40M$248.90M$-68,300,000
    EBITDA$571.30M$689.70M$206.40M$821.00M$1.00B$545.80M$520.40M$684.70M$947.70M$656.40M$463.20M$-16,200,000
    EBIT$132.40M$377.70M$-69,200,000$557.30M$757.20M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M$-141,200,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BIIB

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and BeOne Medicines (ONC)

    This article summarizes recent analyst ratings for three healthcare companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB), and BeOne Medicines (ONC). Wells Fargo assigned a Buy rating to GEHC with an $85 price target, while RBC Capital maintained Buy ratings for Biogen and BeOne Medicines, setting price targets of $260 and $450 respectively. The article highlights the analysts' success rates and provides consensus ratings and price targets for each company.

    The Globe and Mail•8/26/26•
    Bullish

    Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and BeOne Medicines (ONC)

    The article provides an overview of recent bullish analyst ratings for three healthcare companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB), and BeOne Medicines (ONC). Wells Fargo assigned a Buy rating to GEHC, RBC Capital maintained a Buy rating on Biogen, and RBC Capital also maintained a Buy rating on BeOne Medicines, all with specific price targets and analyst consensus ratings. The report highlights the optimism in the Healthcare sector based on these analyst insights.

    The Globe and Mail•8/26/26•
    Bullish

    Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and BeOne Medicines (ONC)

    Three analysts from Wells Fargo and RBC Capital have issued bullish ratings for GE Healthcare Technologies Inc (GEHC), Biogen (BIIB), and BeOne Medicines (ONC). Larry Biegelsen of Wells Fargo rated GEHC a Buy with an $85 price target, while Brian Abrahams and Leonid Timashev of RBC Capital maintained Buy ratings for Biogen and BeOne Medicines, setting price targets of $260 and $450 respectively. The article highlights the average analyst consensus and potential upside for each stock based on current levels.

    The Globe and Mail•8/26/26•
    Bullish

    Invst LLC Purchases Shares of 3,867 Marathon Petroleum Corporation $MPC

    Invst LLC has acquired a new stake of 3,867 shares in Marathon Petroleum Corporation, valued at approximately $989,000. Institutional investors and hedge funds now own 76.77% of the company, which recently reported strong quarterly earnings of $17.73 EPS and declared a $1.00 quarterly dividend. Analysts currently maintain a "Moderate Buy" rating for Marathon Petroleum with an average price target of $312.50.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Biogen entscheidet sich für Veeva Vault CRM

    Biogen has selected Veeva Vault CRM for global deployment to accelerate the delivery of medicines to patients. This partnership extends Biogen's strategic collaboration with Veeva, aiming to leverage Vault CRM's advanced capabilities for commercial strategy, especially for complex therapies. Vault CRM is part of the Vault CRM Suite, which supports the "Agentic Commercial" model powered by AI to ensure patients receive appropriate medications.

    PR Newswire•8/25/26•
    Somewhat-Bullish

    Frequently Asked Questions About BIIB

    Does BIIB pay dividends?
    Biogen Inc (BIIB) does not currently pay a regular dividend.
    What is BIIB's P/E ratio?
    Biogen Inc has a price-to-earnings (P/E) ratio of 15.51.
    What is BIIB's market cap?
    Biogen Inc (BIIB) has a market capitalization of $32.28B with a current stock price of $216.65.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In